tbuckley/cabot-search huggingface dataset:
Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
Authors: Paul Johannet, Wenke Liu, David Fenyo, Megan Wind-Rotolo, Michelle Krogsgaard, Janice M. Mehnert, Jeffrey S. Weber, Judy Zhong, Iman Osman
Journal: Clinical Cancer Research (2022)

Abstract Purpose: Adjuvant immunotherapy produces durable benefit for patients with resected melanoma, but many develop recurrence and/or immune-related adverse events (irAE). We investigated whether baseline serum autoantibody (autoAb) signatures predicted recurrence and severe toxicity in patients treated with adjuvant nivolumab, ipilimumab, or ipilimumab plus nivolumab. Experimental Design: This study included 950 patients: 565 from CheckMate 238 (408 ipilimumab versus 157 nivolumab) and 385 from CheckMate 915 (190 nivolumab versus 195 ipilimumab plus nivolumab). Serum autoAbs were profiled using the HuProt Human Proteome Microarray v4.0 (CDI Laboratories, Mayaguez, PR). Analysis of baseline differentially expressed autoAbs was followed by recurrence and severe toxicity signature building for each regimen, testing of the signatures, and additional independent validation for nivolumab using patients from CheckMate 915. Results: In the nivolumab independent validation cohort, high recurrence score predicted significantly worse recurrence-free survival [RFS; adjusted HR (aHR), 3.60; 95% confidence interval (CI), 1.98–6.55], and outperformed a model composed of clinical variables including PD-L1 expression (P &amp;lt; 0.001). Severe toxicity score was a significant predictor of severe irAEs (aHR, 13.53; 95% CI, 2.59–86.65). In the ipilimumab test cohort, high recurrence score was associated with significantly worse RFS (aHR, 3.21; 95% CI, 1.38–7.45) and severe toxicity score significantly predicted severe irAEs (aHR, 11.04; 95% CI, 3.84–37.25). In the ipilimumab plus nivolumab test cohort, high autoAb recurrence score was associated with significantly worse RFS (aHR, 6.45; 95% CI, 1.48–28.02), and high severe toxicity score was significantly associated with severe irAEs (aHR, 23.44; 95% CI, 4.10–212.50). Conclusions: Baseline serum autoAb signatures predicted recurrence and severe toxicity in patients treated with adjuvant immunotherapy. Prospective testing of the signatures that include datasets with longer follow-up and rare but more severe toxicities will help determine their generalizability and potential clinical utility. See related commentary by Hassel and Luke, p. 3914
The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma
Authors: Peiyu Yang, Fan Zhou, Yujun Dong, Guangxun Gao, Hua Xue, Xinyue Liang, Shanshan Yu, Weiling Xu, Yanping Ma, Xiaoqi Qin, Mengyao Li, Yun Dai, Fengyan Jin
Journal: Blood Cancer Journal (2022)
Asia-Pacific Colorectal Screening Score Combined With Stool DNA Test Improves the Detection Rate for Colorectal Advanced Neoplasms
Authors: Junfeng Xu, Long Rong, Fang Gu, Peng You, Hui Ding, Huihong Zhai, Bangmao Wang, Yanqing Li, Xianzong Ma, Fumei Yin, Lang Yang, Yuqi He, Jianqiu Sheng, Peng Jin
Journal: Clinical Gastroenterology and Hepatology (2022)
Targeting the liver in dementia and cognitive impairment: Dietary macronutrients and diabetic therapeutics
Authors: Nicholas J. Hunt, Devin Wahl, Lara J. Westwood, Glen P. Lockwood, David G. Le Couteur, Victoria C. Cogger
Journal: Advanced Drug Delivery Reviews (2022)

Many people living with dementia and cognitive impairment have dysfunctional mitochondrial and insulin-glucose metabolism resembling type 2 diabetes mellitus and old age. Evidence from human trials shows that nutritional interventions and anti-diabetic medicines that target nutrient-sensing pathways overcome these deficits in glucose and energy metabolism and can improve cognition and/or reduce symptoms of dementia. The liver is the main organ that mediates the systemic effects of diets and many diabetic medicines; therefore, it is an intermediate target for such dementia interventions. A challenge is the efficacy of these treatments in older age. Solutions include the targeted hepatic delivery of diabetic medicines using nanotechnologies and titration of macronutrients to optimize hepatic energy metabolism.
Increased cancer burden among pesticide applicators and others due to pesticide exposure
Authors: Michael C. R. Alavanja, Matthew K. Ross, Matthew R. Bonner
Journal: CA A Cancer Journal for Clinicians (2013)

Abstract A growing number of well‐designed epidemiological and molecular studies provide substantial evidence that the pesticides used in agricultural, commercial, and home and garden applications are associated with excess cancer risk. This risk is associated both with those applying the pesticide and, under some conditions, those who are simply bystanders to the application. In this article, the epidemiological, molecular biology, and toxicological evidence emerging from recent literature assessing the link between specific pesticides and several cancers including prostate cancer, non‐Hodgkin lymphoma, leukemia, multiple myeloma, and breast cancer are integrated. Although the review is not exhaustive in its scope or depth, the literature does strongly suggest that the public health problem is real. If we are to avoid the introduction of harmful chemicals into the environment in the future, the integrated efforts of molecular biology, pesticide toxicology, and epidemiology are needed to help identify the human carcinogens and thereby improve our understanding of human carcinogenicity and reduce cancer risk. CA Cancer J Clin 2013;. © 2013 American Cancer Society.
79P Molecular characterization of KRAS NSCLC all stages: A single-center cohort
Authors: C. Climent Vicente, N. Lopez Zurita, J. Giner Joaquin, S. Soriano, P. Ribera Fernandez, M. Rodriguez, P. Andreu Cobo, M. Busquets Godall, M. Fragio Gil, O. Cano i Cano, A. Carrasco Navas, M.S. Sierra Boada, L. Vila Martinez
Journal: Annals of Oncology (2022)
841P Effects of immune checkpoint inhibitor-based combination therapies on the gut microbiota in advanced melanoma patients
Authors: J. Li, L. Xu, Z. Peng, H. Jiang, F. Chao, Y. Ding, J.M. Moll, D. Li, X. Wen, J. Wang, Q. Ding, L. Zhang, K. Kristiansen, S. Brix, X. Zhang
Journal: Annals of Oncology (2022)
279O ctDNA detection in cerebrospinal fluid and concordance with the primary tumor in a multicenter prospective study of patients with glioma
Authors: S. Cabezas-Camarero, R. Pérez-Alfayate, V. García-Barberán, M. Gandía, P. García-Feijóo, I. López-Cade, I. Casado-Fariñas, N. Cerón, M.J. Sotelo Lezama, P. Pérez Segura
Journal: Annals of Oncology (2022)
978P Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
Authors: A.K. Ganti, M. Rothe, P.K. Mangat, E. Garrett-Mayer, E.G. Dib, H. Duvivier, E. Ahn, D. Behl, H. Borghaei, A.S. Balmanoukian, A. Gaba, R. Li, K. Osei-Boateng, R. Thota, R. O'Lone, G.N. Grantham, S. Halabi, R.L. Schilsky
Journal: Annals of Oncology (2022)
544P Feasibility of two different first-line carboplatin plus paclitaxel regimens in elderly women with ovarian cancer: A retrospective study
Authors: N. Delanoy, E. Ashton, S. Mebarki, M. Gisselbrecht, B. Nicaise, H. Azais, M. Koual, A-S. Bats Mongardon, L. Fournier, M-A. Le Frère-Belda, J. Medioni, E. Paillaud, S. Oudard
Journal: Annals of Oncology (2022)
472P Prognostic markers in patients (pts) with solid tumors submitted to bispecific T-cell engagers in phase I (phI) clinical trials
Authors: M.T. Cunha, S. Ammari, J-M. Michot, A. Laparra, A. Geraud, P. Martin Romano, P. Vuagnat, None C. Sarkozy, A. Gazzah, R. Bahleda, K. Ouali, F-X. Danlos, V. Goldschmidt, A. Hollebecque, A. Marabelle, S. Postel-Vinay, C. Massard, S. Ponce Aix, S. Champiat, C. Baldini
Journal: Annals of Oncology (2022)
801P Neoadjuvant checkpoint inhibitor immunotherapy (IMT) for resectable mucosal melanoma (MM)
Authors: J.J-Y. Ho, J. Mattei, M. Tetzlaff, M. Williams, M. Davies, A. Diab, I.C. Glitza, J. Mcquade, S. Patel, H.A. Tawbi, M. Wong, C. Yee, S.B. Fisher, E.Y. Hanna, E.Z. Keung, M. Ross, S.Y. Su, S.C. Faria, P. Nagaraja, R. Amaria
Journal: Annals of Oncology (2022)
787O Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial
Authors: J.C. Becker, S. Ugurel, U. Leiter-Stoppke, F. Meier, R. Gutzmer, S. Haferkamp, L. Zimmer, E. Livingstone, T. Eigentler, A. Hauschild, F. Kiecker, J.C. Hassel, P. Mohr, M. Fluck, I. Thomas, M. Garzarolli, I. Grimmelmann, K. Drexler, S. Eckhardt, D. Schadendorf
Journal: Annals of Oncology (2022)
918P Improving TNM staging predictive value with PET/CT imaging features and deep learning model in non-small cell lung cancer
Authors: E. Giovannini, G. Giovacchini, F. Tutino, L. Florimonte, A. Milano, L. Dellavedova, C.M.R. Bareggi, A. Castello, C. Aschele, M. Castellani, A. Ciarmiello
Journal: Annals of Oncology (2022)
423P Fruquintinib plus sintilimab in refractory repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Preliminary clinical results and biomarker analyses from a phase II study
Authors: W. Zhang, Y. Sun, Z. Jiang, T. Liu, C. Gong, L. Yang, Y. Xin, D. Huang, A. Zhou
Journal: Annals of Oncology (2022)
984P Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD)
Authors: S.M. Gadgeel, J. Gainor, F. Cappuzzo, E. Garralda, D.H. Lee, J. Mazieres, D-W. Kim, V. Zhu, G. Lopes, S. Miller, M. Nowicka, H. Trinh, S.M. Arndorfer, A. Rahman, J. Noe, Q. Zhang, V. Subbiah
Journal: Annals of Oncology (2022)
354P NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302)
Authors: A. Coveler, A. Skolariki, K.K. Ciombor, H. Marijon Jourdier, J. Graham, M.L. Peters, S.A. Cohen, M. Myers, E.M. Oelmann, J. Bloss, S.P. Blagden, A. de Gramont, J.D. Berlin, T.R.J. Evans
Journal: Annals of Oncology (2022)
656MO Phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma
Authors: A. Bhatia, Z. Chen, J. Bruce, C.E. Steuer, D.P. Zandberg, J.W. Riess, D. Mitchell, T.H. Davis, M. Patel, V. Kaur, S. Arnold, T.K. Owonikoko
Journal: Annals of Oncology (2022)
775P Treatment of Kaposi sarcoma with immune-checkpoint inhibitors: A systematic review and single-arm meta-analysis
Authors: M. Silveira Vilbert, I. Hirsch, E.C. Koch, T. Pimentel Muniz, D. Pinheiro Xavier, M.F. Silva Almeida Ribeiro, L. Mantle, S. Saibil, A. Spreafico, M.O. Butler, D. Hogg
Journal: Annals of Oncology (2022)
833P Longer follow up of a real-world study of cemiplimab in advanced cutaneous squamous cell carcinoma: Focus on late toxicities and long term benefit
Authors: P. Quaglino, A. Baggi, R. Depenni, M. Guida, P.A. Ascierto, P. Queirolo, K. Peris, F. Spagnolo, L. Bianchi, F. De Galitiis, M. Zamparini, I. Proietti, R. Marconcini, A. Botticelli, V. Barbieri, S. Alfieri, M.C. Fargnoli, M. Occelli, P. Bossi
Journal: Annals of Oncology (2022)
127P Better than RECIST and faster than iRECIST: Defining the immunotherapy progression decision score to better manage progressive tumors on immunotherapy
Authors: Y. Belkouchi, None H. Talbot, N. Lassau, L. Lawrance, S. Farhane, R. Feki-Mkaouar, J. Vibert, P-H. Cournede, A. Marabelle, S. Ammari, S. Champiat
Journal: Annals of Oncology (2022)
856P Characterization of patients with brain metastases from metastatic uveal melanoma
Authors: T. Pimentel Muniz, E.C. Koch, M.F. Silva Almeida Ribeiro, M.T. Silveira, D.P. Arteaga Ceballos, P.A. Jablonska, L. Mantle, I. Hirsch, H. Krema, A. Spreafico, S. Saibil, D. Hogg, D. Shultz, M.O. Butler
Journal: Annals of Oncology (2022)
132TiP Biomarker assessments in daNIS-3: A phase II study of NIS793 and other new investigational drug combinations with standard-of-care (SoC) therapy vs SoC alone for the second-line treatment of patients (pts) with metastatic colorectal adenocarcinoma (mCRC)
Authors: S. Kasper, N.H. Segal, F. Rivera, C. Tournigand, Y. Cheng, P. Deshpande, N. Amirouchene Angelozzi, A.P. Bento Pereira da Silva, A. St-Pierre, S. Kopetz
Journal: Annals of Oncology (2022)
892P Hedgehog (Hh) activation in neuroendocrine neoplasms (NENs)
Authors: C. Blanco Abad, P. Saiz Lopez, R. Alcaraz Ortega, E. Garcia Toro, C. Garcia Giron, P. Muñiz Rodriguez, J.L. Catoya Villa, S. de la Torre Lazaro, B. de Frutos Gonzalez, I. Rodriguez Ledesma, C. Gutierrez Perez, M. Vela, M. Pumares Gonzalez, N. Espinosa Cabria, G. Crespo Herrero
Journal: Annals of Oncology (2022)
381P A tumor-informed, hybrid-capture based ctDNA assay for minimal residual disease (MRD) detection in colorectal cancer (CRC) patients after curative surgery
Authors: S-W. Han, S. Heo, Y. Lim, W. Lee, H-P. Kim, S.Y. Kim, D. Bang, K.J. Park, S.T. Oh, C.S. Yoo, S-B. Kang, Y-J. Kim, T-Y. Kim
Journal: Annals of Oncology (2022)
642P Frequency and impact of retreatment in relapsed refractory multiple myeloma (RRMM): Real-world survey conducted in 5 European countries (United Kingdom, France, Germany, Italy, Spain)
Authors: A. Bailey, S. Perera, None T. d’Estrube, A. Ribbands, E. Luke, P. Feng Wang
Journal: Annals of Oncology (2022)
808P Postoperative adjuvant radiotherapy can reduce the local recurrence of nasal cavity and paranasal sinus mucosal melanoma: A prospective design, retrospective analysis and case–control study
Authors: B. Lian, Y. Yang, L. Si, L. Zhou, Z. Chi, X. Sheng, L. Mao, X. Wang, C-L. Cui, B. Zheng, J. Guo
Journal: Annals of Oncology (2022)
142P Effectiveness and safety of pegylated liposomal doxorubicin- cyclophosphamide vs. epirubicin-cyclophosphamide as adjuvant chemotherapy for stage I and II HER2-negative breast cancer: An interim analysis of phase II randomized trial
Authors: L-M. Tseng, F-M. Chen, S-T. Chen, T-F. Cheng, T-Y. Chao, M-S. Dai, W-Y. Kao, D-R. Chen, L-C. Liu, H.C. Wang, H-T. Chang, B.W. Wang, J-C. Yu, S.C. Chen, K-H. Liao, M-F. Hou
Journal: Annals of Oncology (2022)
185P Prospective study to evaluate pathological complete response after neoadjuvant therapy in breast cancer: Are we ready to avoid surgery?
Authors: E.M.C. Rossi, A.M. De Scalzi, A. Girardi, None F. Pesapane, A. Invento, V. dominelli, F. De Lorenzi, V. Sacchini, P. Veronesi
Journal: Annals of Oncology (2022)
249P A retrospective analysis on capecitabine and vinorelbine combination in metastatic breast cancer: The MARCELLINO study
Authors: M. de Scordilli, L. Bortot, L. Cucciniello, F. Totaro, R. Mazzeo, M. Alberti, L. Palmero, G. Targato, A. Dri, F. Pravisano, G. Zapelloni, C. Lisanti, S. Spazzapan, A.M.M. Minisini, M. Mansutti, M. Bonotto, L. Gerratana, G. Fasola, F. Puglisi
Journal: Annals of Oncology (2022)
674P Initial curative management for localized/locally advanced head and neck squamous cell carcinomas (LAHNSCC): Exclusive (chemo)radiation (CRT) or S/IC (surgery or induction chemotherapy) – The EPOCKS study
Authors: J. Fayette, C. Dalban, P. Zrounba, S. Racadot, D. Girodet, S. Chabaud, E. Reyt, M. Poupart, J.M. Prades, M. Burgy, D. Cellier, P. Ceruse, J. Leval, P. Muller, P. Manipoud, I.L. Ray-Coquard, G. Thibault
Journal: Annals of Oncology (2022)
144P Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study
Authors: A. Bardia, T.M. Fernando, P.A. Fasching, V. Quiroga Garcia, Y.H. Park, J.M. Giltnane, C. Xue, V. Lopez Valverde, J. Steinseifer-Szabo, P.D. Pérez-Moreno, H.M. Moore, S.A. Hurvitz
Journal: Annals of Oncology (2022)
CN43 Addressing the professional and educational issues for the cancer nursing and allied health professions workforce: A collaborative, strategic, UK-wide approach
Authors: J. Armoogum, D. Bell, K. Bowles, K. Campbell, J. Davis, M. Fores, M.R. Foulkes, R. Hammond, V. Lavender, S. Lilley, L. Potter, V. Taylor
Journal: Annals of Oncology (2022)
981P A phase IIa study to evaluate safety and efficacy of rezivertinib (BPI-7711) in locally advanced or metastatic/recurrent treatment-naïve NSCLC patients with EGFR mutation
Authors: Y-K. Shi, J. Zhou, Y. Zhao, B. Zhu, L. Zhang, X. Li, J. Fang, J. Shi, Z. Zhuang, S. Yang, D. Wang, H. Yu, L. Zhang, R. Zheng, M. Greco, T. Wang, F. Mo
Journal: Annals of Oncology (2022)
533P Real-world data of treatment and outcome of patients with relapsed ovarian cancer (OC) in Germany (QS ovar of the AGO study group)
Authors: P. Harter, A. du Bois, F. Hilpert, M. Kerkmann, J. Sehouli, S. Mahner, N. de Gregorio, L. Hanker, F. Heitz, F. Marmé, L. Woelber, L. Holtmann, G. Elser, J. Pfisterer
Journal: Annals of Oncology (2022)
473P Phase I study of GFH018, a small molecular TGF-βRI inhibitor, in patients (pts) with advanced solid tumors
Authors: Y. Guo, W. Zishu, H. Zhou, H. Pan, None W. Han, Y. Deng, None Y. Zhang, H. Ren, H. Zhang, S. Wang, Y. Zhang, J. Li
Journal: Annals of Oncology (2022)
1015P Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1 negative or weakly positive advanced non-small cell lung cancer after disease progression on platinum-based therapy: WJOG10317L study (EMERALD)
Authors: Y. Zenke, S. Niho, A. Nakamura, T. Okamoto, S. Hara, Y. Akazawa, Y. Hosomi, H. Hayashi, S. Teraoka, T. Yokoyama, T. Ozaki, K. Ueno, H. Gyotoku, T. Misumi, K. Nakagawa, N. Yamamoto, M. Tsuboi
Journal: Annals of Oncology (2022)
726P Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)
Authors: M. Zang, Q. Li, H. Pang, X. Hu, R. Li, G. Yuan, W. Li, Y. Guo, J. Chen
Journal: Annals of Oncology (2022)
1066P Tumor microenvironment (TME) of HRAS mutated non-small cell lung cancer (NSCLC)
Authors: A. Trabolsi, E. Rodriguez, S. Kareff, J.A. Ocejo Gallegos, J. Yin, P. Walker, H. Mamdani, J.J. Nieva, H. Borghaei, C. Nabhan, M. Nagasaka, S. Puri, S.V. Liu, B. Halmos, G. Lopes
Journal: Annals of Oncology (2022)
397P Early decreases in KRAS mutant allele frequency (MAF) predicts clinical benefit to the PLK1 inhibitor onvansertib in combination with FOLFIRI/bev in 2L treatment of metastatic colorectal carcinoma (mCRC)
Authors: H-J. Lenz, M. Ridinger, E. Samuelsz, T. Smeal, D. Ahn
Journal: Annals of Oncology (2022)
754P A phase I/IIa dose escalation study of AFM24 in patients with epidermal growth factor receptor-expressing (EGFR) solid tumors: Results from phase I
Authors: A.B. El-Khoueiry, J.S. Lopez, O. Saavedra, M. Awad, J. Thomas, C. Tiu, E. Garralda, B. Rehbein, G. Hintzen, K. Pietzko, C. Raab, E. Rajkovic, P. Ravenstijn, D. Rivas, M. Emig
Journal: Annals of Oncology (2022)
398P Effectiveness and safety of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A real-world multicenter retrospective study with focus on sequential treatment
Authors: C. Signorelli, M. Schirripa, M.G. Chilelli, M.A. Calegari, M. Basso, A. Anghelone, J. Lucchetti, A. Minelli, L. Angotti, C. Morelli, E. Dell'Aquila, A. Cosimati, D. Gemma, M. Ribelli, D.C. Corsi, G. Arrivi, F. Zoratto, M.G. Morandi, F. Santamaria, R. Saltarelli, E.M. Ruggeri
Journal: Annals of Oncology (2022)
455MO NUC-7738 in patients with advanced solid tumours: Phase I results from the NuTide:701 phase I/II study
Authors: S.N. Symeonides, A. Skolariki, N.R.M. Haris, Z. Boh, M. Myers, E.M. Oelmann, J.D. Bloss, R. Plummer, S.P. Blagden
Journal: Annals of Oncology (2022)
1052P Comprehensive molecular profiling of squamous non-small cell lung cancer by smoking status
Authors: J. Reuss, N. Gandhi, P. Walker, B. Halmos, C. Aggarwal, J. Xiu, S.P. Patel, A. VanderWalde, S.S. Ramalingam, S.V. Liu
Journal: Annals of Oncology (2022)
664P A multicentre retrospective analysis of recurrent/metastatic (RM) nasopharyngeal cancer (NPC) from non-endemic areas: Results in the pre-immunotherapy era
Authors: P. Bossi, A. Alberti, M. Zamparini, E. Orlandi, S. Grisanti, A. Trama, C. Resteghini, R. Mesia Nin, I. Mohamad, E. Ozyar, M. Buglione, M. Airoldi, S. Vecchio, L. Livi, B. Cirauqui Cirauqui, M. El-Sherify, S. Ursino, A. Argiris, I. Linares Galiana, L.F. Licitra
Journal: Annals of Oncology (2022)
212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)
Authors: S.M. Tolaney, A. Chan, K. Petrakova, S. Delaloge, M. Campone, H. Iwata, P. Peddi, P.A. Kaufman, E. de Kermadec, Q. Liu, P. Cohen, G. Paux, S-A. Im
Journal: Annals of Oncology (2022)
458MO Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers (Ca) (MEDIPAC)
Authors: J. Lim, S. Raghav, A. Wong, W.P. Yong, R.A. Soo, C.E. Chee, S.C. Lee, B-C. Goh, R.A. Dent, J.J. Chan, K.Y.K. Wong, S. d/o Nathan Jeraj, L. Kwok, G. Schiavon, A. Foxley, D.S. Tan
Journal: Annals of Oncology (2022)
68MO Generalization of a deep learning model for HER2 status predictions on H&amp;E-stained whole slide images derived from 3 neoadjuvant clinical studies
Authors: M. Hägele, K-R. Müller, C. Denkert, A. Schneeweiss, B.V. Sinn, M. Untch, M.T. Van Mackelenbergh, C. Jackisch, V. Nekljudova, T. Karn, M. Alber, F. Marmé, C. Schem, E. Stickeler, P.A. Fasching, V. Mueller, K.E. Weber, B. Lederer, S. Loibl, F. Klauschen
Journal: Annals of Oncology (2022)
972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial
Authors: G. Zalcman, A-C. Madroszyk Flandin, O. Molinier, C. Dayen, T. Egenod, D. Debieuvre, S. Beaucaire-Danel, A. Dixmier, E. Pichon, S. Galland Girodet, E. Giroux-Leprieur, N. Cloarec, J. Cadranel, J. Otto, P. Romand, A. Langlais, F. Morin, M. Antoine, V. Westeel, A.C. Toffart
Journal: Annals of Oncology (2022)
838P Patterns of response/progressive disease (PD) and management following PD with anti-PD-1 (PD1) in patients (pts) with advanced cutaneous squamous cell carcinoma (cSCC)
Authors: J. Mo, A-S. Bohne, C. Gaudy Marqueste, N. Della Marta, L. Festino, C. Chen, S.N. Lo, J.J. Park, P.A. Ascierto, R. Ladwa, W. Xu, J.J. Grob, A. Hauschild, A.M. Menzies, G.V. Long, M.S. Carlino, I. Pires da Silva
Journal: Annals of Oncology (2022)
727TiP A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-3
Authors: G.K. Abou-Alfa, J. Fan, J. Heo, Y. Arai, J.P. Erinjeri, C.K. Kuhl, R. Lencioni, Z. Ren, A. Zeng, B. Evans, G. Cohen, M. Kudo
Journal: Annals of Oncology (2022)
355P The prognostic role of HIF-1α and NF-κB expression in RAS wild-type metastatic colorectal cancer (mCRC) patients: A Turkish oncology group (TOG) study
Authors: A. Demirkiran, F. Kılınç, M.Z. Koçak, M. Korkmaz, D. Demirkıran, M. Karakurt Eryılmaz, M. Araz, M. Karaağaç, M. Artac
Journal: Annals of Oncology (2022)
647TiP A multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2
Authors: S.P. Iyer, I.B. Greenwell, L.K. Shea, J-H. Lee, M. Muller
Journal: Annals of Oncology (2022)
667P Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours
Authors: D.S. Hong, M. Tahara, C. Baik, J.R. Bauman, J. Gilbert, M.S. Brose, J.E. Grilley-Olson, T. Patil, R. McDermott, L.E. Raez, J.M. Johnson, L. Shen, R. Norenberg, L. Dima, C. Mussi, X. Le, A.E. Drilon
Journal: Annals of Oncology (2022)